Skip to content

Jade Biosciences

US · JBIO #3338 by market cap Listed 2021
15.31 +0.25 +1.66%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 14.70 -2.39%
After-hours 15.31 0.00%
24.7113.4115.312026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on JBIO?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +2.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 16.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is above its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Return on equity -89.2% Better than 6%
Return on invested capital -67.6% Better than 4%
Momentum C-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -28.3% Better than 19%
6-month return -31.1% Better than 17%
12-month return (ex latest month) 24.2% Better than 64%
Distance below 52-week high 45.3% Better than 23%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 21.1x Better than 98%
Debt to assets 0.2% Better than 97%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 244.0% Better than 96%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -5.14%
1M +3.03%
3M -27.89%
6M -34.40%
YTD -0.78%
1Y +33.36%
3Y -96.91%
5Y -96.85%

Key statistics

Price & volume

Prev close
15.06
Open
15.00
Day range
15.00 - 15.54
Avg price
15.33
Volume
1.02M
Turnover
15.65M
Amplitude
3.59%
52-week range
11.32 - 28.00

Valuation

P/E
-4.80
P/E (TTM)
-8.37
P/B
2.33
EPS
-3.19
Net profit
-220.71M
Net assets
455.47M

Share structure

Market cap
1.06B
Float cap
894.15M
Shares out
69.19M
Float shares
58.40M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-06-30
52-week range 24% of range
11.32 28.00

45.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-5.55M net over the window

Short interest

Shares short
10.37M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Jade Biosciences (JBIO)?

Jade Biosciences last traded at 15.31. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Jade Biosciences's market cap?

About 1.06B.

What is the P/E ratio of Jade Biosciences?

The trailing twelve-month P/E is -8.37. The Valuation tab shows it against the stock's own five-year range.

Does Jade Biosciences pay a dividend?

Jade Biosciences does not currently pay a regular dividend.

Is Jade Biosciences a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 52.67, which implies 244.0% upside from the current price. This is not investment advice.

What is Jade Biosciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Jade Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Jade Biosciences discussion 0 comments

Add a comment